Multi-Dose NASH Clinical Trial Underway for Durect’s DUR-928

Durect Corporation believes their single, small molecule agent, DUR-928, might be able to hit all the targets of NASH. On Wednesday, the company announced that the first patient has been enrolled in their new phase 1b trial evaluating multiple doses of DUR-928.